E-cadherin expression and mutation in endometrial carcinomas and endometrial hyperplasias.
- Author:
Sung Ook HWANG
1
;
Eun Seop SONG
;
Moon Whan IM
;
Byoung Ick LEE
;
Woo Young LEE
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine,Inha University, Incheon, Korea. p0928@inha.ac.kr
- Publication Type:Original Article
- Keywords:
E-cadherin;
IHC;
Endometrial carcinoma;
Mutation
- MeSH:
Adenocarcinoma;
Cadherins;
Cell Adhesion;
Endometrial Hyperplasia;
Endometrial Neoplasms;
Female;
Incidence;
Lymph Nodes;
Neoplasm Metastasis;
Prognosis
- From:Korean Journal of Obstetrics and Gynecology
2009;52(3):328-335
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Reduced tumor cell adhesion is associated with invasive growth and unfavorable prognosis. In endometrial carcinoma, the prognostic impact of adhesion marker such as E-cadherin is partly known. The purpose of this study is to investigate the correlation of the expression and the mutation of E-cadherin in endometrioid endometrial adenocarcinomas and endometrial hyperplasias and to correlate their results with various clinicopathological factors. METHODS: The expression of E-cadherin by using immunohistochemical staining (IHC) and the mutation of E-cadherin gene by using polymerase chain reaction-single stranded conformational polymorphism (PCR-SSCP) and sequencing were performed in tissues of 20 endometrial adenocarcinomas and 30 endometrial hyperplasias. The results were compared with previously known prognostic factors such as the stage, tumor grade and lymph node metastasis. RESULTS: Decreased expression of E-cadherin was detected in 13 of 30 (43.3%) endometrial carcinomas and in 1 of 20 (5%) endometrial hyperplasias (P=0.009). There was no statistical significance of the mutation of E-cadherin gene in between the endometrial carcinomas and endometrial hyperplasias (6.7%: 0%) (P=0.06). The incidence of the expression loss of E-cadherin in endometrial carcinomas also showed significantly higher with tumor grade 3, tumor stage above Ic or lymph nodal metastasis (P=0.01, P=0.02, P=0.03). CONCLUSION: Decreased expression of E-cadherin was detected significantly higher in endometrial carcinomas than endometrial hyperplasias. And the incidence of decreased expression of E-cadherin was more frequent in advanced stage, high histopathologic grade, and lymph nodal metasis. The mutation of E-cadherin gene was detected in only 2 cases. These results suggests that the expression of E-cadherin seems to be important in endometrial carcinomas and associated with aggressive subgroups. But the mutation of E-cadherin gene would not be related to endometrial carcinomas.
